Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game! (Q38601929)

4 September 2017

Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game! (English)

1 reference

4 September 2017

Michael A Nauck

1

1 reference

PMCID

4764228

4 September 2017

Juris J Meier

series ordinal

2

1 reference

4 September 2017

12 May 2014

1 reference

Journal of Diabetes Science and Technology

4 September 2017

1 reference

4 September 2017

8

1 reference

4 September 2017

4

1 reference

4 September 2017

895-897

1 reference

Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604

4 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

Incretin therapy and islet pathology: a time for caution

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

European drugs agency clashes with scientists over safety of GLP-1 drugs

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

Investigations editor's reply to Holt and to Barnett and O'Hare

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4764228

FDA is to assess data linking type 2 diabetes drugs with pancreatitis

31 August 2018

1 reference

12 December 2020

Hyperplasia from GLP-1 drugs is "not a surprise," say researchers

1 reference

12 December 2020

Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

1 reference

12 December 2020

Pressure mounts for companies to hand over data on antidiabetes drugs linked to pancreatic harm

1 reference

12 December 2020

Identifiers

DOI

10.1177/1932296814532874

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

PMCID

4764228